Hyperoxaluria Clinical Trial
Official title:
Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate
Primary hyperoxaluria is an inborn error of metabolism that results in marked overproduction
of oxalate by the liver. The excess oxalate causes kidney failure and can cause severe
systemic disease due to oxalate deposition in multiple body tissues.
Metabolic pathways that lead to oxalate are poorly understood, but recent evidence suggests
that hydroxyproline may play a role. Sources of hydroxyproline include the diet and bone
turnover. If hydroxyproline can be confirmed as a significant factor in primary
hyperoxaluria, diet modification might be of value in reducing the severity of disease.
This protocol, in which hydroxyproline labelled with a cold isotope is infused intravenously
in patients with primary hyperoxaluria, will allow the researchers to measure the amount of
oxalate produced from hydroxyproline. The contribution of hydroxyproline metabolism to the
amount of oxalate excreted in urine in will be able to be determined for patients with each
of the known types of primary hyperoxaluria.
The purpose of this study is to determine the contribution of hydroxyproline metabolism to
urinary oxalate and glycolate excretion in patients with primary hyperoxaluria.
Oxalic acid (COOH)2 is an end product of metabolism that is synthesized mainly in the liver.
The researchers have estimated that 10 - 20 mg is synthesized in the body of healthy adults
each day. The main precursor of oxalate is glyoxylate (CHO•COOH). The bulk of the glyoxylate
formed is normally transaminated to glycine (NH2•CH2•COOH) by alanine: glyoxylate
aminotransferase (AGT) or reduced to glycolate (CHOH•COOH) by glyoxylate reductase (GR). Less
than 10% of the glyoxylate is oxidized to oxalate by lactate dehydrogenase (LDH). In
individuals with the disease, primary hyperoxaluria, AGT, GR, or hydroxy-oxoglutarate
aldolase (HOGA) enzyme is deficient and the amount of oxalate synthesized by the liver
increases to 80 - 300 mg per day. The increased oxalate excreted in urine can cause damage to
kidney tissue. Calcium oxalate stones may form in the kidney or calcium oxalate crystals may
deposit in renal tubules and the renal parenchyma (nephrocalcinosis). An increased rate of
oxalate synthesis could also contribute to idiopathic calcium oxalate stone disease.
Understanding the pathways of endogenous oxalate synthesis and identifying strategies that
decrease oxalate production could be beneficial for individuals with these diseases.
Hydroxyproline is the primary source of glyoxylate identified in the body. Daily collagen
turnover of bone results in the formation of 300 - 450 mg of hydroxyproline, which cannot be
re-utilized by the body and is broken down. This metabolism yields 180 - 250 mg of
glyoxylate. Further hydroxyproline is obtained from the diet, primarily from meat and
gelatin-containing products. The bulk of the glyoxylate formed is converted to glycine by the
liver enzyme AGT, some to glycolate and a small amount to oxalate. The proportion of these
metabolites is not known with any certainty. In this study, a quantitative estimate of the
metabolites formed will provide estimates of the contribution of hydroxyproline turnover to
daily oxalate production.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06138327 -
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
|
Phase 1 | |
Completed |
NCT02547805 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
|
Phase 2 | |
Completed |
NCT02289755 -
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
|
Phase 2 | |
Completed |
NCT03095885 -
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
|
N/A | |
Recruiting |
NCT02780297 -
Prospective Research Rare Kidney Stones (ProRKS)
|
||
Completed |
NCT01127087 -
Oxazyme in Patients With Hyperoxaluria
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05443932 -
Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients
|
Phase 4 | |
Completed |
NCT04756024 -
Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children
|
||
Completed |
NCT02503345 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
|
Phase 2 | |
Completed |
NCT00199459 -
Proteomic Study of Urinary Stone Disease
|
N/A | |
Completed |
NCT04119765 -
Plasma Oxalate in Patient With Short Bowel
|
||
Completed |
NCT02404701 -
Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk
|
N/A | |
Completed |
NCT00283387 -
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
|
Phase 2 | |
Completed |
NCT00587041 -
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
|
Phase 1/Phase 2 | |
Completed |
NCT04571359 -
Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate
|
||
Withdrawn |
NCT00280215 -
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria
|
Phase 3 | |
Completed |
NCT00588120 -
Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria
|
Phase 1 |